Vol. 6 No. 10 (2026): October
Reimbursement Reviews

Pegzilarginase (Loargys)

decorative image of the issue cover

Published October 23, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pegzilarginase (Loargys), 5 mg/mL, for IV infusion after dilution or subcutaneous injection.
  • Indication: Treatment of hyperargininemia in adults and pediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction.